TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Analgesic Potentials of Preoperative Pregabalin,Magnesium Sulphate and Their Combination in Acute Post-thoracotomy Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. ASA status of1 or 2~2. Patients undergoing thoracotomy~3. Body mass index (BMI): Less than forty and more than twenty.~Exclusion Criteria:~- 1. Known sensitivity or contraindication to drugs used in the study. 2. History of psychological disorders and/or chronic pain. 3. Patients receiving medical therapies that are considered to result in tolerance to opioids.~4. Significant liver or kidney diseases that will affects the pharmacokinetics of study drugs.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Pregabalin & placebo (Type: ACTIVE_COMPARATOR): : will receive single dose oral Pregabalin 300 mg one hour preoperative and 200 ml of normal saline over 20 min.
- Magnesium sulphate & Placebo (Type: ACTIVE_COMPARATOR): will receive preoperative single dose IV Magnesium Sulphate 50mg /kg infused over 20 minutes diluted in 200 ml normal saline and a placebo capsule similar to pregabalin 300 mg.
- Pregabalin & Magnesium sulphate (Type: ACTIVE_COMPARATOR): : will receive single dose oral pregabalin 300mg one hour preoperative and single dose IV Magnesium Sulphate 50mg /kg infused over 20 minutes diluted in 200 ml normal saline.
- Placebo (Type: PLACEBO_COMPARATOR): will receive placebo medications at the same time and route of administration of other groups.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: BOTOX® Treatment in Pediatric Upper Limb Spasticity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Minimum weight of 10 kg/22 lb~* Upper limb spasticity due to cerebral palsy or stroke~Exclusion Criteria:~* Muscular dystrophy, myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or mitochondrial disease~* Uncontrolled epilepsy~* Botulinum Toxin therapy of any serotype for any condition within the last 6 months~* Previous surgical treatment of the study limb (except tendon lengthening), or planned surgery of the study limb during the study~* Previous casting of the study limb for spasticity within 6 months or with a dynamic splint within 3 months, or planned casting or dynamic splinting for spasticity of the study limb or affected lower limb during the study

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- BOTOX® 3 U/kg (Type: EXPERIMENTAL): Participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 3 units (U) per kilogram (kg) of body weight (3 U/kg) into specified muscles of the upper limb on Day 1. Participants received weekly occupational therapy (OT).
- BOTOX® 6 U/kg (Type: EXPERIMENTAL): Participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 6 U per kg of body weight (6 U/kg) into specified muscles of the upper limb on Day 1. Participants received weekly OT.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received intramuscular injections of normal saline (placebo) into specified muscles of the upper limb on Day 1. Participants received weekly OT.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tamoxifen or Letrozole in Treating Women With Ductal Carcinoma in Situ

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of ductal carcinoma in situ (DCIS) on core biopsy~* No evidence of contralateral breast disease or palpable masses on breast examination~* No presence or suspicion of invasive cancer, including contralateral invasive cancer, on core biopsy and MRI~* No documented ipsilateral axillary adenopathy~* Planning to undergo lumpectomy or mastectomy~* Estrogen receptor (ER)-positive tumor by immunohistochemistry~PATIENT CHARACTERISTICS:~* Female patient~* Premenopausal or postmenopausal~  * Postmenopausal is defined by any of the following:~    * No spontaneous menses for \>= 1 year~   * Bilateral oophorectomy~   * Radiation castration and amenorrheic for \>= 3 months~   * Follicle-stimulating hormone (FSH) \> 20 IU/L AND off all hormonal therapy (e.g., hormone replacement therapy or birth control pills) for \>= 1 month~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No co-morbidities contraindicating the use of tamoxifen, including any of the following:~  * Prior history of thrombotic events~ * History of hypercoagulable state~ * History of endometrial hyperplasia~ * Abnormal vaginal bleeding~* No history of contrast dye-related allergies/reactions~* No history of metal-containing prostheses or implants~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- tamoxifen or letrozole (Type: EXPERIMENTAL): tamoxifen or letrozole work in treating women with ductal carcinoma in situ

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Asfotase Alfa in Juvenile Patients With Hypophosphatasia (HPP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Written informed consent from parent or legal guardian prior to participation~2. Patients \> 5 and \< 12 years of age with open growth plates at time of enrollment~3. Tanner stage of 2 or less indicating pre-pubescence~4. Documented history of HPP, as evidenced by:~   * Presence of HPP-related rickets on skeletal radiographs of the wrist and knee~  * Serum alkaline phosphatase (ALP) below age-adjusted normal range~  * Plasma PLP at least twice the upper limit of normal~5. 25(OH) vitamin D level \> 20 ng/mL~6. Ability of patient and parent/guardian to comply with study requirements~Exclusion Criteria:~1. Serum calcium or phosphorus below age-adjusted normal range~2. History of sensitivity to any study drug constituent~3. Medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study compliance, including all prescribed evaluations and follow-up activities~4. Treatment with an investigational drug within 1 month before start of study drug~5. Current enrollment in any other study involving an investigational new drug, device, or treatment for HPP (e.g., bone marrow transplantation)~6. Current evidence of a treatable form of rickets~7. Prior treatment with bisphosphonates~8. Bone fracture or orthopedic surgery within the past 12 months that, in the opinion of the Investigator would interfere with the ability of study patient to comply with study protocol~9. Major congenital abnormality other than those associated with HPP

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- 2 mg/kg (Type: ACTIVE_COMPARATOR): 2 mg/kg subcutaneous injection three times per week.
- 3 mg/kg (Type: ACTIVE_COMPARATOR): 3 mg/kg subcutaneous injection three times per week.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Does Framing and Humor Improve the Effectiveness of Messages About COVID-19 Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Are 21 years of age or older.~* Have not participated in the cognitive interview.~* Have not yet received a COVID vaccine.~* Are registered with MTurk in the United States.~* Have completed \>= 5,000 HIITs within the MTurk system~* Have a HIIT approval rating of \>= 97%~* Rate their agreement with the following statement as less than or equal to 50 out of 100: To what extent do you agree with the following: The FDA only authorizes COVID vaccines that are safe and effective.~Exclusion Criteria:~* Are younger than 21 years of age~* Participated in the cognitive interviews~* Have already received a COVID vaccine.~* Are not registered with MTurk in the US~* Have completed \< 5,000 HIITS~* Have a HIIT approval rating of \<97%~* Rate their agreement with the following statement as greater than 50 out of 100: To what extent do you agree with the following: The FDA only authorizes COVID vaccines that are safe and effective.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Vaccine Corrective Control (Type: ACTIVE_COMPARATOR): A message that explains why people are hesitant to accept the FDA authorized COVID vaccines are safe and effective and how the vaccines are evaluated as safe and effective by FDA.
- Vaccine corrective with economic recovery framing (Type: EXPERIMENTAL): The content of the control message with the addition of the text, If everyone gets vaccinated, we can keep schools, stores, and other businesses open so more Americans can keep working and supporting their families. The message will also include a picture of an open for business sign.
- Vaccine corrective with freedom framing (Type: EXPERIMENTAL): The content of the control message with the addition of the text, Everyone getting vaccinated is the key to freedom! A vaccine can give us the freedom to hang out with friends, shop, and worship together again safely. The message will also include a picture of an American flag.
- Vaccine corrective with humor (Type: EXPERIMENTAL): The content of the control message with the addition of the text, Unfortunately, everyone getting vaccinated means leaving the house again. The message will include a meme of a cat being pulled/rescued from a window with text boxes labeling the cat as People at home working in sweatpants and the rescuer as COVID Vaccines.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Kunxian Capsule in Treatment Patients With Early Ankylosing Spondylitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 16 to 65 years old, having signed the informed consent;~* fulfill the ESSG criteria for diagnosis of SpA; not fulfill the 1984 modified NewYork criteria for AS;~* BASDAI score more than 4;~* stop taking DMARDs for at least 4 weeks;~* NSAIDs dosage has been stable for at least 4 weeks;~Exclusion Criteria:~* Intra-articular injection of cortisone within 3 months.~* History of heart failure, multiple sclerosis, COPD, lymphoma or other tumors;~* Accompanied by fibromyalgia or other rheumatic diseases;~* Female of pregnancy or breast feeding;~* History of mental disease and poor compliance.~* History of drug abuse or alcoholism.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Sulfasalazine (Type: ACTIVE_COMPARATOR): Sulfasalazine is a drug in treatment RA, AS and ulcerative colonitis. In this study, Sulfasalazine is used to act as an active comparator to access the efficacy of kunxian capsule.
- placebo (Type: PLACEBO_COMPARATOR): The placebo capsule was used to be a comparator of kunxian capsule

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pain Relief at Iliac Crest Bone Harvest Sites in Spine Surgery Using Bupivacaine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients 18 years of age or older undergoing posterior cervical, thoracic, or lumbar surgery~* willingness to participate in the study.~Exclusion Criteria:~* individuals who underwent surgical intervention in the past 6 months~* previous iliac crest bone harvesting~* history of tumor and spondyloarthropathies (rheumatoid arthritis, seronegative arthritis)~* history of adverse reaction to local anesthetic~* history of severe pelvic and hip conditions that can interfere with the outcome assessment of the study~* opioid addiction~* pregnancy~* acute mental illness~* uncontrolled major depression and any other psychiatric disorders~* prisoners~* non-english speaking patients~* inability to understand the informed consent and demands of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bupivacaine (Type: ACTIVE_COMPARATOR): This group will receive bupivacaine (10ml of 0.5%) administered directly into the surgical wound at the iliac crest bone harvest site.
- Saline (Type: PLACEBO_COMPARATOR): This group will receive normal saline (10ml) administered directly into the surgical wound at the iliac crest bone harvest site.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Testing a Digital Intervention for Adolescents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 13-17 years of age~* US resident~* Perceived Stress Scale Score ≥ 10~* Ruminative Responses Scale Score ≥ 14~* Ability and willingness to complete study activities~* Willingness and access to using a digital intervention via mobile application or web browser~Exclusion Criteria:~* Current or past user of any Happify platform~* Non-US Resident~* Perceived Stress Scale Score \< 10~* Ruminative Responses Scale Score \< 14

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Happify Teens (Type: ACTIVE_COMPARATOR): Happify Teens is a digital well-being intervention that can be accessed via mobile application or web browser
- Waitlist Control (Type: NO_INTERVENTION): Waitlist Control Condition

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Sirolimus in LAM

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 or older~* Signed and dated informed consent~* Diagnosis of LAM based on compatible chest CT scan and a) biopsy or cytology consistent with LAM, or b) presence of tuberous sclerosis, angiomyolipoma or chylous pleural effusion; or c) a VEGF-D level of at least 800 pg/ml~* Forced expiratory volume in one second (FEV1) of 70% or less of predicted value after administration of a bronchodilator~Exclusion Criteria:~* Known allergy to sirolimus~* History of heart attack, angina, or stroke due to clogging, narrowing, and hardening of the arteries and blood vessels~* Significant hematologic or hepatic abnormality (transaminase levels greater than three times the upper limit of normal, HCT less than 30%, platelets less than 80,000/cubic mm, adjusted absolute neutrophil count less than 1,000/cubic mm, total white blood cell count less than 3,000/cubic mm)~* Intercurrent infection at the time treatment with sirolimus begins~* Any surgery involving entry into a body cavity or requiring three or more sutures within 8 weeks of initiation of study drug~* Use of an investigational drug within the 30 days prior to random assignment~* Uncontrolled hyperlipidemia~* Previous lung transplant or currently on lung transplant list~* Unable to attend scheduled study visits~* Unable to perform pulmonary function tests~* Creatinine levels greater than 2.5 mg/dl~* Chylous ascites severe enough to affect diaphragmatic function~* Pleural effusion severe enough to affect pulmonary function, as determined by the study physician~* History of acute pneumothorax within the 2 months prior to study entry~* History of malignancy within the 2 years prior to study entry (except for squamous or basal cell skin cancer)~* Use of estrogen containing medication within the thirty days prior to randomization~* Unable or unwilling to use adequate contraception~* Pregnant, breastfeeding, or plans to become pregnant within the next 2 years

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active Agent (Sirolimus) (Type: EXPERIMENTAL): Participants receive sirolimus daily for 1 year and are followed with serial pulmonary function tests, 6-minute walk tests, and symptom and QOL questionnaires over a 2-year period.
- Placebo Arm (Type: PLACEBO_COMPARATOR): Participants receive placebo daily for 1 year and followed with serial pulmonary function tests, 6-minute walk tests, and symptom and QOL questionnaires over a 2-year period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of ENV515 Travoprost Extended Release (XR) in Patients With Bilateral Ocular Hypertension or Primary Open Angle Glaucoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of either ocular hypertension or open angle glaucoma in both eyes.~* Are currently treated with topical PGA for ocular hypertension in both eyes.~* Patients who in the opinion of the Investigator: have an IOP in both eyes that is considered to be adequately controlled, can be safely withdrawn from IOP medications in both eyes during the washout period, and who are not considered to be at significant risk for disease progression throughout the trial.~Exclusion Criteria:~* Eye surgery (including cataract surgery) within the past 3 months.~* History of glaucoma related surgery.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): ENV515-1 and ENV515-3 implants in Study Eye for 28 days
- Cohort 2 (Type: EXPERIMENTAL): Two ENV515-3 implants in Study Eye for 12 months with optional 6 month and 3 month extensions (total of 21 months)
- Cohort 3 (Type: EXPERIMENTAL): One or two ENV515-3-2 implants in Study Eye with optional 6 months and additional 6 month extension (total of 24 months)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult subjects with moderately to severely active rheumatoid arthritis~* Subjects must have a DAS28(CRP) (Disease Activity Score using C-Reactive Protein) greater than or equal to 3.2 at baseline (there is no minimum CRP score required to qualify)~* Subjects must have at least 5/68 tender joints plus 5/66 swollen joints assessed at screening or baseline~* Subject must treated with and MTX (methotrexate) dose (oral and/or injectable) of 15 mg or more per week (no upper limit on dose) for at least 12 weeks prior to screening~* Subject is either biologic-naïve or has only one prior biologic disease-modifying antirheumatic drug (i.e. abatacept, anakinra, certolizumab, etanercept, golimumab, infliximab, or tocilizumab)~Exclusion Criteria:~* Previous exposure to adalimumab (Humira), rituximab (Rituxan), natalizumab (Tysabri), efalizumab (Raptiva)~* Subject has been treated with intra-articular or parenteral administration of corticosteroids within 4 weeks of screening~* Subject has diagnosis or history of gout or pseudogout~* Subject has undergone joint surgery within 12 weeks of screening (at joints to be assessed by ultrasound)~* Subject has history of chronic arthritis diagnosed before age 16 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adalimumab + Low Dose Methotrexate (Type: EXPERIMENTAL): Open-label adalimumab (40 mg subcutaneous every other week) plus blinded, low dose methotrexate (7.5 mg orally once weekly).
- Adalimumab + High Dose Methotrexate (Type: ACTIVE_COMPARATOR): Open-label adalimumab (40 mg subcutaneous every other week) plus blinded, high dose methotrexate (20 mg orally once weekly).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete